BYOOVIZ
Google image searchProduct monograph
Active ingredient
ranibizumab, 10 MG/ML
DIN: 02525852
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVITREAL
Description: SINGLE USE VIALS
Schedule: Prescription / Schedule D
Company: SAMSUNG BIOEPIS CO., LTD
Date: 01-MAR-2023
ATC:
- S01 — OPHTHALMOLOGICALS (ATC, ATC/DDD, )
- S01L — OCULAR VASCULAR DISORDER AGENTS (ATC, ATC/DDD)
- S01LA — Antineovascularisation agents (ATC, ATC/DDD)
- S01LA04 — RANIBIZUMAB (ATC/DDD)
Reference brand drug: Lucentis
